David Andes, MD
Infectious Disease · Madison, WINPI 1154398857
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,304 of the $19,893 with a category attached, or 92.0%. 5 manufacturers reported payments, led by Astellas Pharma US Inc at 25.9% of the total. 2025 is the largest year on record at $6,720, 5.6 times the $1,203 reported in 2019. Among infectious disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $795.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$5K
- Melinta Therapeutics, LLC$5K
- Genentech, Inc.$4K
- Merck$3K
- F. Hoffmann-la Roche AG$3K
Across 8 payments — averaging $35,132 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$144K
- Melinta Therapeutics, LLC$89K
- Paratek Pharmaceuticals, Inc.$25K
- Merck$20K
- Mayne Pharma Commercial LLC$3K
What the payments were for
- Consulting fees$18,30492%
- Travel & lodging$1,5898%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 14 | $5,154 |
| Melinta Therapeutics, LLC | 2 | $4,600 |
| Genentech, Inc. | 4 | $4,129 |
| Merck | 2 | $3,400 |
| F. Hoffmann-la Roche AG | 3 | $2,610 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRESEMBA$5,154
- Rezzayo$4,600
- Non-Covered Product$2,610
How this compares
$19,893 in reported general payments places this provider in the 95th percentile of 133 infectious disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 47 | $2,949 |
| Doxycycline Hyclate | 17 | $1,260 |
| Fluconazole | 15 | $780 |
| Meropenem | 14 | $754 |
| Azithromycin | 100 | $353 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Madison
- James LevinMadison$167K
- Robert StrikerMadison$80K
- Shravan KethireddyMadison$22K
- Nasia SafdarMadison$22K
- Barry FoxMadison$541
- Dawd SirajMadison$364
- Bradley SmithMadison$310
- John CherianMadison$259
- Amanda CarlsonMadison$146
- Mark MounajjedMadison$134
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.